1. Insulin degludec improves health‐related quality of life (SF‐36®) compared with insulin glargine in people with Type 2 diabetes starting on basal insulin: a meta‐analysis of phase 3a trials. Issue 2 (21st January 2013) Authors: Freemantle, N.; Meneghini, L.; Christensen, T.; Wolden, M. L.; Jendle, J.; Ratner, R. Journal: Diabetic medicine Issue: Volume 30:Issue 2(2013:Feb.) Page Start: 226 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Insulin degludec/liraglutide (IDegLira) maintains glycaemic control and improves clinical outcomes, regardless of pre‐trial insulin dose, in people with type 2 diabetes that is uncontrolled on basal insulin. Issue 2 (28th November 2019) Authors: Meneghini, L.; Doshi, A.; Gouet, D.; Vilsbøll, T.; Begtrup, K.; Őrsy, P.; Ranthe, M. F.; Lingvay, I. Journal: Diabetic medicine Issue: Volume 37:Issue 2(2020) Page Start: 267 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Once‐daily initiation of basal insulin as add‐on to metformin: a 26‐week, randomized, treat‐to‐target trial comparing insulin detemir with insulin glargine in patients with type 2 diabetes. Issue 8 (13th March 2013) Authors: Meneghini, L.; Kesavadev, J.; Demissie, M.; Nazeri, A.; Hollander, P. Journal: Diabetes, obesity & metabolism Issue: Volume 15:Issue 8(2013:Aug.) Page Start: 729 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗